Gilead/Galapagos alliance hit again as IPF drug is binned
fibrosis, Galapagos, Gilead Sciences, idiopathic pulmonary fibrosis, partnership, respiratory disease
0 Comment
respiratory disease
AstraZeneca’s respiratory biologic fails again in COPD
AZ, COPD, Fasenra, MedImmune, respiratory biologic, respiratory disease
0 Comment
AstraZeneca (AZ) and MedImmune, have announced that the latest trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) did not provide a statistically-significant reduction in exacerbations.